← Volver a la portada
Asia · Mercados regionales · Yicai Global

JW Therapeutics’ CAR-T Drug Enters China’s Reimbursement List With 78% Price Cut; Can Still Be Profitable, CEO Says

Publicado por Yicai Global · China hace 13 h
JW Therapeutics’ CAR-T Drug Enters China’s Reimbursement List With 78% Price Cut; Can Still Be Profitable, CEO Says
JW Therapeutics’ CAR-T Drug Enters China’s Reimbursement List With 78% Price Cut; Can Still Be Profitable, CEO Says · Yicai Global

Resumen detallado

The reimbursement price has been slashed by 78 percent from its previous selling price to roughly CNY288,600 (USD 42,984) per dose. Under China’s current medical insurance…

(Yicai) Nov. 16 -- JW Therapeutic’s innovative CAR-T cell therapy Carteyva has been included in China’s newly released 2026 National Reimbursement Drug List, making it eligible for coverage under the country's medical insurance system. Despite the 78 percent price drop, the Chinese drugmaker’s chairman still believes the product can remain profitable.

Carteyva, also known as the relmacabtagene autoleucel injection, has been added to the National Reimbursement Drug List, Tian Feng, who is also chief executive officer of Shanghai-based JW Therapeutics, said during an investor briefing yesterday.

The reimbursement price has been slashed by 78 percent from its previous selling price to roughly CNY288,600 (USD 42,984) per dose. Under China’s current medical insurance reimbursement arrangements, patients will be expected to pay less than CNY100,000 (USD14,895) out of pocket for the treatment.

The new pricing was the result of a very careful decision-making process, Tian said. “I can state clearly that the reimbursement price is sufficient to support the firm’s sustainable operations. We will not lose money on every dose we sell.”

The high price of CAR-T therapies is mainly due to substantial manufacturing costs. In particular, lentiviral vectors, a key raw material, are expensive. As a result, the fully loaded production cost of one dose of Carteyva was as high as CNY550,000 (USD81,922) last year.

The company plans to cut manufacturing costs by developing its own lentiviral vectors and localising the production of selected raw materials and consumables, Tian said. Combined with economies of scale resulting from increased patient demand following inclusion in the national reimbursement scheme, these initiatives are expected to help the product reach profitability.

JW Therapeutic’s proprietary lentiviral vector manufacturing platform has reached an advanced stage of development, according to the firm’s WeChat account.

Tian also noted that CAR-T therapies are used in fewer than 4…

W…

Inicio del artículo, extracto de Yicai Global. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en Yicai Global Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.yicaiglobal.com)

También te puede interesar